KR20230098175A - 바이러스성 질 주변부 질환의 예방 또는 치료를 위한 의약 조성물 - Google Patents

바이러스성 질 주변부 질환의 예방 또는 치료를 위한 의약 조성물 Download PDF

Info

Publication number
KR20230098175A
KR20230098175A KR1020237014225A KR20237014225A KR20230098175A KR 20230098175 A KR20230098175 A KR 20230098175A KR 1020237014225 A KR1020237014225 A KR 1020237014225A KR 20237014225 A KR20237014225 A KR 20237014225A KR 20230098175 A KR20230098175 A KR 20230098175A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
vaginal
compound
nonionic surfactant
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014225A
Other languages
English (en)
Korean (ko)
Inventor
히로시 오노기
데츠오 야마구치
가츠히코 사토
Original Assignee
가부시키가이샤 키노파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 키노파마 filed Critical 가부시키가이샤 키노파마
Publication of KR20230098175A publication Critical patent/KR20230098175A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237014225A 2020-10-28 2021-02-19 바이러스성 질 주변부 질환의 예방 또는 치료를 위한 의약 조성물 Pending KR20230098175A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-180339 2020-10-28
JP2020180339 2020-10-28
PCT/JP2021/006418 WO2022091442A1 (ja) 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物

Publications (1)

Publication Number Publication Date
KR20230098175A true KR20230098175A (ko) 2023-07-03

Family

ID=81382191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014225A Pending KR20230098175A (ko) 2020-10-28 2021-02-19 바이러스성 질 주변부 질환의 예방 또는 치료를 위한 의약 조성물

Country Status (11)

Country Link
US (1) US20230398107A1 (https=)
EP (1) EP4238565B1 (https=)
JP (1) JP7606239B2 (https=)
KR (1) KR20230098175A (https=)
CN (1) CN115734782A (https=)
CA (1) CA3199945A1 (https=)
ES (1) ES3045576T3 (https=)
PL (1) PL4238565T3 (https=)
TW (1) TWI890738B (https=)
WO (1) WO2022091442A1 (https=)
ZA (1) ZA202304812B (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508386A (ja) 1999-08-30 2003-03-04 シエーリング アクチエンゲゼルシャフト 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
JP5349309B2 (ja) * 2007-08-03 2013-11-20 株式会社キノファーマ 抗ｄｎａウイルス作用を有するアニリン誘導体
JP2010189337A (ja) * 2009-02-19 2010-09-02 Asahi Breweries Ltd 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP6138635B2 (ja) * 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法
WO2020218518A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508386A (ja) 1999-08-30 2003-03-04 シエーリング アクチエンゲゼルシャフト 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ajiro et. al., Clin Cancer Res. 2018 Sep 15; 24(18):4518-4528. doi: 10.1158/1078-0432. CCR-17-3119. Epub 2018 Apr 30
Okamoto et. al., Antiviral Res. 2015 Nov; 123:1-4. doi: 10.1016/j.antiviral. 2015.08.012. Epub 2015 Aug 21
Tanaka et. al., Antiviral Res. 2016 Sep; 133:156-64. doi: 10.1016/j.antiviral. 2016.08.008. Epub 2016 Aug 8
Yamamoto et. al., J Clin Invest. 2014 Aug; 124(8):3479-88. doi: 10.1172/JCI73805. Epub 2014 Jul 8

Also Published As

Publication number Publication date
WO2022091442A1 (ja) 2022-05-05
JP7606239B2 (ja) 2024-12-25
EP4238565C0 (en) 2025-09-24
PL4238565T3 (pl) 2025-12-22
ES3045576T3 (en) 2025-11-28
EP4238565A4 (en) 2024-10-09
CA3199945A1 (en) 2022-05-05
EP4238565A1 (en) 2023-09-06
JPWO2022091442A1 (https=) 2022-05-05
EP4238565B1 (en) 2025-09-24
TW202216142A (zh) 2022-05-01
TWI890738B (zh) 2025-07-21
US20230398107A1 (en) 2023-12-14
ZA202304812B (en) 2024-08-28
CN115734782A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
KR100479521B1 (ko) Ｎ-피페리디노-3-피라졸카르복사미드 유도체, 그것의 염 및 그것들의 용매화물의 경구 투여용 약제학적 조성물
KR102164693B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
KR102735893B1 (ko) 에스테트롤 성분을 함유하는 구강분해성 투여 단위
TWI415633B (zh) Solid preparations containing enteric solid dispersions
KR20160124914A (ko) 치료적으로 활성인 화합물의 약제학적 조성물
CN101422585A (zh) 含有莪术油的药物组合物的制药用途
JP2002003492A (ja) ジプラシドン組成物
EA024609B1 (ru) Лечение боли, обусловленной дислокацией базального слоя эндометрия
TWI617325B (zh) 含醋酸烏利司他之聯合微粉化產物
CN1953741A (zh) 欧司哌米芬的固体制剂
JP6680297B2 (ja) 経口投与用医薬組成物
JP7344911B2 (ja) 頸部障害の処置のためのロピナビルおよびリトナビル
KR102894055B1 (ko) 약학 제형, 약학 제형을 제조하기 위한 방법 및 이를 포함하는 의약
AU2020392193B2 (en) Pharmaceutical compositions
CN111686084A (zh) 一种盐酸小檗碱谷维素片剂在治疗糖尿病中的应用
JP7606239B2 (ja) ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物
JP7420735B2 (ja) 注射用組成物
HK40083240A (en) Pharmaceutical composition for preventing or treating viral perivaginal disease
CN114191404B (zh) 一种多替拉韦片剂及其制备方法
WO2020088364A1 (zh) 一种用于抗病毒感染的药物组合物及制备方法
KR102210982B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
JP2006069994A (ja) 発癌抑制用経口投与剤
US20020015732A1 (en) Formulation of a 5 alpha reductase inhibitor for oral administrtion, and a preparation process and use thereof
WO2025147598A1 (en) Device system and use for hpv infection and cervical intraepithelial neoplasia
WO2025160227A1 (en) Advantageous compounds for treatment of hpv infection and hpv-induced neoplasia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000